All In MedTech

Device Trial Radar · NCT00973362

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

Clinical Evaluation of the APTIMA® HPV Assay on the TIGRIS® DTS® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens

Last checked: Nov 20, 2026Latest source record: Jan 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12,896

Actual

Start

Mar 2008

Primary completion

Jun 2013

Study completion Apr 2014

Sponsor

Lead sponsor
Gen-Probe, IncorporatedNot on our public-company list
Sponsor type
Industry
First posted
Sep 9, 2009

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Screening
Who can join
Female only, from 21 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide data on the performance of the APTIMA HPV Assay using the TIGRIS System in detecting HPV types that may cause cervical cancer.

Conditions

  • Human Papillomavirus Infection

Interventions

  • APTIMA HPV AssayDevice

    The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer ("high-risk types"). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44).

  • FDA-Approved HPV DNA TestDevice

    A FDA-Approved HPV DNA Test is used as the comparator assay.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjunct Study Arm: Compare Assay Performance for Aptima HPV Assay to a FDA-Approved HPV Assay for Detecting CIN2+Time frame: Baseline Evaluation
  2. Adjunct Study Arm: Compare Assay Performance for FDA-Approved HPV DNA Assay to a FDA-Approved HPV Assay for Detecting CIN2+Time frame: Baseline Evaluation

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • NEA Clinic Women's Clinic

    Jonesboro, Arkansas

  • San Fernando Valley Research

    Canoga Park, California

  • Healthcare Partners of Monterey Park

    Los Angeles, California

14 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.